Detrimental effects of thyroid hormone analog DITPA in the mouse heart: Increased mortality with in vivo acute myocardial ischemia-reperfusion

M. A. Hassan Talukder, Fuchun Yang, Yoshinori Nishijima, Chun An Chen, Lin Xie, Shouvik D. Mahamud, Anuradha Kalyanasundaram, John D. Bonagura, Muthu Periasamy, Jay L. Zweier

Research output: Contribution to journalArticle

Abstract

There is emerging evidence that treatment with thyroid hormone (TH) can improve postischemic cardiac function. 3,5-Diiodothyropropionic acid (DITPA), a TH analog, has been proposed to be a safer therapeutic agent than TH because of its negligible effects on cardiac metabolism and heart rate. However, conflicting results have been reported for the cardiac effects of DITPA. Importantly, recent clinical trials demonstrated no symptomatic benefit in patients with DITPA despite some improved hemodynamic and metabolic parameters. To address these issues, dose-dependent effects of DITPA were investigated in mice for baseline cardiovascular effects and postischemic myocardial function and/or salvage. Mice were treated with subcutaneous DITPA at 0.937, 1.875, 3.75, or 7.5 mg·kg-1·day-1 for 7 days, and the results were compared with untreated mice for ex vivo and/or in vivo myocardial ischemia-reperfusion (I/R). DITPA had no effects on baseline body temperature, body weight, or heart rate; however, it mildly increased blood pressure. In isolated hearts, baseline contractile function was significantly impaired in DITPA-pretreated mice; however, postischemic recovery was comparable between untreated and DITPA-treated groups. In vivo baseline cardiac parameters were significantly affected by DITPA, with increased ventricular dimensions and decreased contractile function. Importantly, DITPA-treated mice demonstrated high prevalence of fatal cardiac rhythm abnormalities during in vivo ischemia and/or reperfusion. There were no improvements in myocardial infarction and postischemic fractional shortening with DITPA. Myocardial sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA), phospholamban (PLB), and heat shock protein (HSP) levels remained unchanged with DITPA treatment. Thus DITPA administration impairs baseline cardiac parameters in mice and can be fatal during in vivo acute myocardial I/R.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume300
Issue number2
DOIs
StatePublished - Feb 2011
Externally publishedYes

Keywords

  • Cardiac function
  • Fatal cardiac rhythm
  • Postischemic recovery

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Detrimental effects of thyroid hormone analog DITPA in the mouse heart: Increased mortality with in vivo acute myocardial ischemia-reperfusion'. Together they form a unique fingerprint.

  • Cite this

    Hassan Talukder, M. A., Yang, F., Nishijima, Y., Chen, C. A., Xie, L., Mahamud, S. D., Kalyanasundaram, A., Bonagura, J. D., Periasamy, M., & Zweier, J. L. (2011). Detrimental effects of thyroid hormone analog DITPA in the mouse heart: Increased mortality with in vivo acute myocardial ischemia-reperfusion. American Journal of Physiology - Heart and Circulatory Physiology, 300(2). https://doi.org/10.1152/ajpheart.00514.2010